Form 4: Trevi Therapeutics Executive Granted Stock Options

James V. Cassella, Chief Development Officer of Trevi Therapeutics, Inc., was granted stock options for 400,000 shares on September 30, 2024.

Summary

• James V. Cassella, the Chief Development Officer of Trevi Therapeutics, Inc., was granted stock options on September 30, 2024.
• The options are for 400,000 shares of Trevi Therapeutics' common stock at an exercise price of $3.34.
• The options vest as to 25% on September 30, 2025, and the remaining 75% vest in equal monthly installments through September 30, 2028.
• The options expire on September 29, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options to an executive, which is neither particularly positive nor negative on its own. The vesting schedule is standard.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders, incentivizing them to improve company performance.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedule of 25% after one year followed by monthly installments is a typical vesting structure.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive company growth.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates